Ultragenyx Pharmaceutical (RARE) Operating Income: 2016-2025
Historic Operating Income for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to -$170.9 million.
- Ultragenyx Pharmaceutical's Operating Income fell 29.47% to -$170.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$544.0 million, marking a year-over-year decrease of 1.54%. This contributed to the annual value of -$536.0 million for FY2024, which is 5.84% up from last year.
- Ultragenyx Pharmaceutical's Operating Income amounted to -$170.9 million in Q3 2025, which was down 58.40% from -$107.9 million recorded in Q2 2025.
- In the past 5 years, Ultragenyx Pharmaceutical's Operating Income ranged from a high of -$82.8 million in Q2 2021 and a low of -$225.1 million during Q3 2022.
- Its 3-year average for Operating Income is -$138.8 million, with a median of -$142.9 million in 2025.
- Its Operating Income has fluctuated over the past 5 years, first slumped by 150.55% in 2022, then soared by 35.53% in 2023.
- Ultragenyx Pharmaceutical's Operating Income (Quarterly) stood at -$102.6 million in 2021, then tumbled by 41.99% to -$145.6 million in 2022, then grew by 16.19% to -$122.0 million in 2023, then dropped by 0.19% to -$122.3 million in 2024, then declined by 29.47% to -$170.9 million in 2025.
- Its last three reported values are -$170.9 million in Q3 2025, -$107.9 million for Q2 2025, and -$142.9 million during Q1 2025.